| Novavax, Inc. (NVAX) Presents at BofA Securities 2025 Health Care Conference (Transcript) |
Novavax, Inc. (NASDAQ:NVAX ) BofA Securities 2025 Health Care Conference May 14, 2025 6:00 PM ET Company Participants John Jacobs - President and CEO Jim Kelly - CFO Ruxandra Draghia-Akli - EVP, Head, R&D Conference Call Participants Alec Stranahan - Bank of America Alec Stranahan Joining Day 2 of the 2025 Bank of America Healthcare Conference. My name is Alec Stranahan, Senior Biotech Analyst covering Novavax at Bank of America. |
seekingalpha.com |
2025-05-15 02:46:05 |
Czytaj oryginał (ang.) |
| Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It |
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects. |
zacks.com |
2025-05-13 14:05:58 |
Czytaj oryginał (ang.) |
| Novavax: Initiating Hold Rating After Strong, But Misunderstood Q1 2025 Earnings Beat |
Initiate coverage on Novavax with a Buy rating; Q1 2025 marks an inflection point with $519M net income and raised revenue guidance to $975M-$1.025B. Novavax's Q1 2025 revenue surged to $667M, driven by $603M from terminated APA agreements and $19M from new vaccine shipments, indicating strong demand. Sanofi partnership converts lower-margin product revenue to higher-margin income, allowing Novavax to focus on R&D and achieve non-GAAP profitability by 2027. |
seekingalpha.com |
2025-05-12 16:45:00 |
Czytaj oryginał (ang.) |
| Why Novavax (NVAX) is a Top Momentum Stock for the Long-Term |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2025-05-09 14:55:57 |
Czytaj oryginał (ang.) |
| NVAX Stock Gains 12% on Q1 Earnings & Sales Beat, '25 Sales View Up |
Novavax posts encouraging first-quarter results on the back of an additional $603 million in revenues recognized from the termination of two advanced purchase agreements. |
zacks.com |
2025-05-09 13:55:14 |
Czytaj oryginał (ang.) |
| COVID Vaccine Maker Novavax Stock Soars 16% - Here's Why |
On Thursday, Novavax Inc. NVAX reported first-quarter 2025 sales of $667 million, compared to $94 million a year ago, beating the consensus of $343.85 million. |
benzinga.com |
2025-05-08 17:31:54 |
Czytaj oryginał (ang.) |
| Novavax, Inc. (NVAX) Q1 2025 Earnings Call Transcript |
Novavax, Inc. (NASDAQ:NVAX ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Luis Sanay - Vice President, Investor Relations John Jacobs - President and Chief Executive Officer Ruxandra Draghia-Akli - Executive Vice President, Head of Research and Development Jim Kelly - Executive Vice President, Chief Financial Officer and Treasurer John Trizzino - President and Chief Operating Officer Conference Call Participants Roger Song - Jefferies Mayank Mamtani - B. Riley Securities Alec Stranahan - Bank of America Securities Tom Shrader - BTIG Eric Joseph - JPMorgan Chris LoBianco - TD Securities Operator Good morning and welcome to Novavax First Quarter 2025 Financial Results and Operational Highlights Conference Call. |
seekingalpha.com |
2025-05-08 15:48:22 |
Czytaj oryginał (ang.) |
| Why This Shrinking Covid-19 Vaccine Stock Jumped 30% |
Novavax has seen its shares plummet since the pandemic because of weakening demand. |
barrons.com |
2025-05-08 15:12:00 |
Czytaj oryginał (ang.) |
| Novavax (NVAX) Beats Q1 Earnings and Revenue Estimates |
Novavax (NVAX) came out with quarterly earnings of $2.93 per share, beating the Zacks Consensus Estimate of $0.71 per share. This compares to loss of $1.05 per share a year ago. |
zacks.com |
2025-05-08 14:16:27 |
Czytaj oryginał (ang.) |
| Novavax swings to profit on lower expenses related to COVID shots |
Novavax on Thursday swung to a first-quarter profit from a year-ago loss, helped by reduced costs related to the development and sale of its COVID-19 vaccines, its only product on the market. |
reuters.com |
2025-05-08 12:06:31 |
Czytaj oryginał (ang.) |
| Novavax Reports First Quarter 2025 Financial Results and Operational Highlights |
FDA feedback on COVID-19 BLA suggests pathway to approval upon alignment on study parameters for the postmarketing commitment requested by FDA SHIELD-Utah study demonstrates that Nuvaxovid® resulted in fewer and less severe reactogenicity symptoms when compared to marketed mRNA vaccine; Nuvaxovid recipients experienced approximately 39% fewer symptoms on average Data presented at World Vaccine Congress showcases Matrix-M ® utility when co-administered with a broad array of vaccine platforms and diseases Strengthened partnership with Takeda in Japan, the third largest pharmaceutical market, with significant improvement in financial terms Raises full year 2025 revenue framework to between $975 million and $1,025 million Reiterates full year 2025 financial guidance for combined R&D and SG&A expenses of between $475 million and $525 million Recorded total revenue of $667 million in the first quarter of 2025 C ompany to host conference call today at 8:30 a.m. ET GAITHERSBURG, Md. |
prnewswire.com |
2025-05-08 12:00:00 |
Czytaj oryginał (ang.) |
| New vaccine chief rocks pharmaceutical stocks |
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss how the biotech and pharma industry is reacting to a new FDA chief of vaccines appointed by President Trump. |
youtube.com |
2025-05-07 15:13:02 |
Czytaj oryginał (ang.) |
| Novavax to Participate in BofA Securities 2025 Health Care Conference |
GAITHERSBURG, Md. , May 7, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the BofA Securities 2025 Health Care Conference. |
prnewswire.com |
2025-05-07 12:00:00 |
Czytaj oryginał (ang.) |
| Novavax to Report First-Quarter Earnings: Is a Beat in Store? |
On NVAX's first-quarter earnings call, investors will likely focus on pipeline updates. |
zacks.com |
2025-05-05 12:15:34 |
Czytaj oryginał (ang.) |
| Novavax Announces Significantly Improved Terms for Collaboration and License Agreement with Takeda for Nuvaxovid® in Japan |
Improved financial terms for Novavax and streamlined operations will help both companies better meet the needs of the Japanese market Nuvaxovid®, a protein-based, non-mRNA COVID-19 vaccine, will continue to be available in Japan, the world's third largest pharmaceutical market GAITHERSBURG, Md. , May 5, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) has updated the terms of the previously announced collaboration and licensing agreement (CLA) with Takeda. |
prnewswire.com |
2025-05-05 12:00:00 |
Czytaj oryginał (ang.) |
| Novavax (NVAX) Flat As Market Gains: What You Should Know |
In the most recent trading session, Novavax (NVAX) closed at $6.41, indicating no shift from the previous trading day. |
zacks.com |
2025-05-02 22:50:38 |
Czytaj oryginał (ang.) |
| Novavax to Report First Quarter 2025 Financial Results on May 8, 2025 |
GAITHERSBURG, Md. , May 1, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its first quarter 2025 financial results and operational highlights at 8:30 a.m. |
prnewswire.com |
2025-05-01 12:00:00 |
Czytaj oryginał (ang.) |
| Why Investors Need to Take Advantage of These 2 Medical Stocks Now |
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates. |
zacks.com |
2025-04-29 13:56:14 |
Czytaj oryginał (ang.) |
| Novavax Appoints Charles Newton to Board of Directors |
GAITHERSBURG, Md. , April 29, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced the appointment of Charles Newton to its board as an independent director. |
prnewswire.com |
2025-04-29 12:00:00 |
Czytaj oryginał (ang.) |
| FDA asks Novavax to complete new clinical trial for delayed COVID-19 shot, WSJ reports |
Federal regulators are asking Novavax to complete an additional clinical trial on its Covid-19 vaccine after previously delaying approval, the Wall Street Journal reported on Friday, citing people familiar with the matter. |
reuters.com |
2025-04-25 19:35:33 |
Czytaj oryginał (ang.) |
| Novavax to Participate in Upcoming March Investor Conferences |
GAITHERSBURG, Md. , Feb. 27, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), today announced that the management team will participate in the following upcoming investor conferences: TD Cowen 45 th Annual Health Care Conference: Fireside Chat Date: Tuesday, March 4, 2025 Time: 9:10 – 9:40 a.m. |
prnewswire.com |
2025-02-27 18:05:00 |
Czytaj oryginał (ang.) |
| Novavax Q4 Loss Narrower Than Expected, Sales Beat Estimates |
NVAX reports encouraging fourth-quarter results. It completes the sale of its Czech Republic manufacturing unit to Novo Nordisk for $200 million. |
zacks.com |
2025-02-27 15:20:31 |
Czytaj oryginał (ang.) |
| Novavax, Inc. (NVAX) Q4 2024 Earnings Call Transcript |
Novavax, Inc. (NASDAQ:NVAX ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Luis Sanay - Vice President, Investor Relations John Jacobs - President and Chief Executive Officer Ruxandra Draghia-Akli - Executive Vice President, Head of Research and Development John Trizzino - President and Chief Operating Officer Jim Kelly - Executive Vice President, Chief Financial Officer and Treasurer Robert Walker - Senior Vice President and Chief Medical Officer Conference Call Participants Roger Song - Jefferies Mayank Mamtani - B. Riley Securities Alec Stranahan - Bank of America Securities Eric Joseph - JPMorgan Vernon Bernardino - H.C. |
seekingalpha.com |
2025-02-27 13:42:35 |
Czytaj oryginał (ang.) |
| Novavax Reports Smaller Q4 Loss, Shifts Focus From Commercializing COVID-19 Vaccine To Maximize Value |
On Thursday, Novavax Inc NVAX reported fourth-quarter 2024 sales of $88.31 million, compared to $291 million a year, beating the consensus of $84.35 million. The decrease was due to lower product sales under APA agreements. |
benzinga.com |
2025-02-27 13:24:10 |
Czytaj oryginał (ang.) |
| Novavax (NVAX) Reports Q4 Loss, Tops Revenue Estimates |
Novavax (NVAX) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.75. This compares to loss of $1.44 per share a year ago. |
zacks.com |
2025-02-27 12:15:29 |
Czytaj oryginał (ang.) |
| Novavax's quarterly loss shrinks as it ramps down spending on COVID vaccines |
Novavax's fourth-quarter loss narrowed on Thursday, helped by reduced selling and administrative expenses of COVID-19 vaccines, its only product on the market. |
reuters.com |
2025-02-27 10:06:57 |
Czytaj oryginał (ang.) |
| Novavax Stock Is Rising. Revenue Beat Estimates. |
Fourth-quarter revenue came in at $88 million, above expectations of 84 million, while Novavax continues to shift away from Covid-19 vaccines. |
barrons.com |
2025-02-27 10:05:00 |
Czytaj oryginał (ang.) |
| Novavax Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights |
Transitioned lead commercial responsibility of Nuvaxovid™ COVID-19 vaccine to Sanofi beginning with the 2025-2026 season Achieved total revenue of $88 million in the fourth quarter of 2024 and $682 million for the full year 2024 Achieved $50 million milestone under Sanofi agreement associated with the pediatric clinical trial database lock for the first cohort Completed $200 million sale of Czech Republic manufacturing facility to Novo Nordisk; reduces annual costs by approximately $80 million Advanced pipeline programs, based on proven and innovative technology platform Ended full year 2024 with over $1 billion in Cash and accounts receivables Provides 2025 financial guidance and revenue framework Company to host conference call today at 8:30 a.m. ET GAITHERSBURG, Md. |
prnewswire.com |
2025-02-27 10:00:00 |
Czytaj oryginał (ang.) |
| What's in Store for These 5 Biotech Stocks This Earnings Season? |
Let's look at five biotech and drug companies, VTRS, PRGO, NVAX, NTLA and IOVA, slated to release their fourth-quarter 2024 results on Feb. 27, 2025. |
zacks.com |
2025-02-24 13:30:24 |
Czytaj oryginał (ang.) |
| Vaccine Stocks Rise as Chinese Scientists Discover a New Coronavirus |
Stocks of MRNA, PFE, NVAX and BNTX rose in anticipation that a new virus in China could trigger another pandemic. |
zacks.com |
2025-02-24 11:30:27 |
Czytaj oryginał (ang.) |
| Novavax (NVAX) Declines More Than Market: Some Information for Investors |
Novavax (NVAX) closed the most recent trading day at $7.92, moving -1.25% from the previous trading session. |
zacks.com |
2025-02-20 20:50:41 |
Czytaj oryginał (ang.) |
| Is Trending Stock Novavax, Inc. (NVAX) a Buy Now? |
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects. |
zacks.com |
2025-02-20 12:05:31 |
Czytaj oryginał (ang.) |
| Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights on February 27, 2025 |
GAITHERSBURG, Md. , Feb. 20, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its fourth quarter and full year 2024 financial results and operational highlights at 8:30 a.m. |
prnewswire.com |
2025-02-20 10:00:00 |
Czytaj oryginał (ang.) |
| Novavax to Report Q4 Earnings: Here's What You Can Expect |
On NVAX's fourth-quarter earnings call, investors will likely focus on updates on its pipeline. |
zacks.com |
2025-02-19 12:40:58 |
Czytaj oryginał (ang.) |
| Novavax (NVAX) Outperforms Broader Market: What You Need to Know |
In the closing of the recent trading day, Novavax (NVAX) stood at $8.19, denoting a +0.74% change from the preceding trading day. |
zacks.com |
2025-02-10 20:46:10 |
Czytaj oryginał (ang.) |
| Novavax (NVAX) Rises But Trails Market: What Investors Should Know |
In the most recent trading session, Novavax (NVAX) closed at $8.45, indicating a +0.24% shift from the previous trading day. |
zacks.com |
2025-02-04 20:51:11 |
Czytaj oryginał (ang.) |
| Vaccine, packaged food stocks fall as Kennedy moves closer to health secretary job |
Shares of vaccine makers and packaged food companies fell on Tuesday after President Donald Trump's pick for U.S. health secretary, Robert F. Kennedy Jr., moved closer to the job after a favorable vote by a Senate panel. |
reuters.com |
2025-02-04 13:51:44 |
Czytaj oryginał (ang.) |
| Vaccine stocks fall as Senate panel advances RFK Jr.'s nomination for HHS secretary |
Shares of vaccine companies fell after a Senate panel voted to advance Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services to the full chamber. |
cnbc.com |
2025-02-04 13:50:33 |
Czytaj oryginał (ang.) |
| Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know |
Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock. |
zacks.com |
2025-02-04 12:06:50 |
Czytaj oryginał (ang.) |
| New Strong Buy Stocks for January 30th |
BBCP, SDVKY, OBK, CDNA and NVAX have been added to the Zacks Rank #1 (Strong Buy) List on January 30, 2024. |
zacks.com |
2025-01-30 09:50:25 |
Czytaj oryginał (ang.) |
| Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It |
Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store. |
zacks.com |
2024-12-24 12:01:23 |
Czytaj oryginał (ang.) |
| Novavax Advances Corporate Growth Strategy Through Sanofi Partnership, Including Achievement of First $50 Million Milestone |
Novavax continues to progress Sanofi agreement by achieving first milestone, with additional milestones and ongoing tiered royalties to come, solidifying a strong model for future partnerships Novavax's COVID-19 vaccine included in Sanofi's two combination vaccine candidates for prevention of influenza and COVID-19, for which Phase 1/2 trials were initiated and Fast Track designation recently granted in the U.S. GAITHERSBURG, Md. , Dec. 13, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced progress in Q4 2024 advancing its corporate growth strategy through its partnership with Sanofi. |
prnewswire.com |
2024-12-13 10:00:00 |
Czytaj oryginał (ang.) |
| Why Is Novavax (NVAX) Up 13.6% Since Last Earnings Report? |
Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2024-12-12 14:36:23 |
Czytaj oryginał (ang.) |
| NVAX Starts Late-Stage Study on COVID-19-Flu Combo & Flu Vaccines |
Novavax is working with the FDA to explore a pathway for accelerated approval of the COVID-19-flu combination and standalone flu vaccines. |
zacks.com |
2024-12-11 10:50:21 |
Czytaj oryginał (ang.) |
| Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know |
Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects. |
zacks.com |
2024-12-10 12:05:19 |
Czytaj oryginał (ang.) |
| Novavax Initiates Phase 3 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza |
Company continuing to work with the U.S. FDA on potential for accelerated approval pathway Novavax intends to partner on both candidates to advance to filing and commercialization GAITHERSBURG, Md. , Dec. 10, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the first participants have been dosed in its COVID-19-Influenza Combination (CIC) and stand-alone seasonal influenza Phase 3 trial. |
prnewswire.com |
2024-12-10 10:00:00 |
Czytaj oryginał (ang.) |
| Novavax to Sell Czech Manufacturing Plant to Novo Nordisk for $200M |
NVAX intends to use the payment from Novo to advance the development of its vaccine pipeline. The deal is expected to be closed by the end of this year. |
zacks.com |
2024-12-05 14:55:22 |
Czytaj oryginał (ang.) |
| 2 Beaten-Down "Pandemic Stocks" to Consider for Contrarian Investors |
Many companies that performed well in the early pandemic years have since fallen off the radar or at least have seen their shares drop substantially during the past three years. Telemedicine Teladoc Health (TDOC 0.64%) and vaccine maker Novavax (NVAX -1.31%) belong in this group: Both have significantly lagged behind the market since 2021. |
fool.com |
2024-12-05 07:30:00 |
Czytaj oryginał (ang.) |
| Novavax to sell Czech manufacturing unit to Novo Nordisk for $200 mln |
COVID-19 vaccine maker Novavax said on Wednesday it will sell its manufacturing facility in Czech Republic to Wegovy-maker Novo Nordisk for $200 million and use the proceeds for its vaccine pipeline. |
reuters.com |
2024-12-04 05:03:29 |
Czytaj oryginał (ang.) |
| Novavax Announces Sale of Czech Republic Manufacturing Site to Novo Nordisk for $200 Million |
Agreement provides significant, non-dilutive capital to Novavax, further enabling the Company to advance its corporate growth strategy of driving value from its pipeline assets and proven technology platform Provides Novavax with $190 million cash payment in 2024 and additional $10 million in 2025, and annual operating cost reductions of approximately $80 million GAITHERSBURG, Md. , Dec. 4, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it has signed a definitive agreement to sell its manufacturing facility in Bohumil, Czech Republic to Novo Nordisk for $200 million. |
prnewswire.com |
2024-12-04 04:00:00 |
Czytaj oryginał (ang.) |
| Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It |
Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store. |
zacks.com |
2024-11-29 12:06:13 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX |
NEW YORK, NY / ACCESSWIRE / November 27, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Novavax, Inc. ("Novavax" or the "Company") (NASDAQ:NVAX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2024-11-27 13:15:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX |
NEW YORK, NY / ACCESSWIRE / November 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Novavax, Inc. ("Novavax" or the "Company") (NASDAQ:NVAX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2024-11-26 22:45:00 |
Czytaj oryginał (ang.) |
| Novavax Cut Its Outlook Despite Beating Third-Quarter Forecasts. Is It A Sell? |
Things were looking up for Novavax stock after the FDA resolved a clinical hold. But the company trimmed its outlook. |
investors.com |
2024-11-26 16:13:01 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX |
NEW YORK, NY / ACCESSWIRE / November 22, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Novavax, Inc. ("Novavax" or the "Company") (NASDAQ:NVAX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2024-11-22 13:00:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX |
NEW YORK CITY, NY / ACCESSWIRE / November 20, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Novavax, Inc. ("Novavax" or the "Company") (NASDAQ:NVAX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2024-11-20 21:45:00 |
Czytaj oryginał (ang.) |
| Novavax, Inc. (NVAX) Jefferies London Healthcare Conference (Transcript) |
Novavax, Inc. (NASDAQ:NVAX ) Jefferies London Healthcare Results Conference November 20, 2024 6:00 AM ET Company Participants Jim Kelly - Executive Vice President, Chief Financial Officer and Treasurer Ruxandra Draghia - Head of R&D Conference Call Participants Roger Song - Jefferies Roger Song Alright. Okay. So, sorry for the couple minutes late, but it's my pleasure. |
seekingalpha.com |
2024-11-20 15:18:06 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX |
NEW YORK , Nov. 18, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Novavax, Inc. ("Novavax" or the "Company") (NASDAQ: NVAX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
prnewswire.com |
2024-11-18 23:12:00 |
Czytaj oryginał (ang.) |
| Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know |
Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock. |
zacks.com |
2024-11-18 12:05:16 |
Czytaj oryginał (ang.) |
| NVAX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Novavax, Inc. |
NEW YORK, NY / ACCESSWIRE / November 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Novavax, Inc. ("Novavax, Inc.") (NASDAQ:NVAX) concerning possible violations of federal securities laws. On October 16, 2024, NVAX announced the Food and Drug Administration placed a clinical hold on the development of the company's combination influenza and Covid-19 (CIC) shot and its stand-alone influenza vaccine. |
accesswire.com |
2024-11-16 21:31:00 |
Czytaj oryginał (ang.) |